Mucoactive therapy in community-acquired pneumonia
- Authors: Zaytsev A.A.1,2, Filon E.A.1
-
Affiliations:
- Burdenko Main Military Clinical Hospital
- BIOTECH University
- Issue: Vol 25, No 9 (2023): Otorhinolaryngology and pulmonology
- Pages: 611-615
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/253577
- DOI: https://doi.org/10.26442/20751753.2023.9.202397
- ID: 253577
Cite item
Full Text
Abstract
Aim. To study the clinical efficacy of Bronchipret® syrup compared with the standard (real-world practice) mucoactive therapy for patients with viral pneumonia.
Materials and methods. The observation study included patients 18–70 years old who presented with productive cough and were admitted to the pulmonology department with medically confirmed community-acquired pneumonia (CAP). The study included 60 patients; Group 1 included 30 patients who received Bronchipret® syrup 5.4 mL 3 times a day for up to 10–14 days. The other 30 patients with CAP were included in Group 2 (control), in which other mucoactive drugs were used at the discretion of the physician: acetylcysteine in 56.7% of patients, ambroxol in 30%, and bromhexine in 13.3%. The duration of therapy was established by a physician for a period of 10–14 days.
Results. A significant decrease in sputum secretion was observed during treatment with Bronchipret® (Group 1) on average on day 4 (after 4.3±1.2 days) and after 4.5±0.9 days in group 2. A decrease in the severity of daytime cough in Group 1 was observed after 4.9±1.2 days vs. 5.1±1.1 days in Group 2. The nocturnal cough stopped in 2.7±1.3 days in Group 1 and 2.6±0.9 days in Group 2.
Conclusion. The data support the use of combined products containing ivy and thyme in patients with CAP and mucolytics.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Andrey A. Zaytsev
Burdenko Main Military Clinical Hospital; BIOTECH University
Author for correspondence.
Email: a-zaicev-a@yandex.ru
ORCID iD: 0000-0002-0934-7313
D. Sci. (Med.), Prof., Burdenko Main Military Clinical Hospital, BIOTECH University
Russian Federation, Moscow; MoscowEkaterina A. Filon
Burdenko Main Military Clinical Hospital
Email: filon_94@mail.ru
Pulmonologist, Burdenko Main Military Clinical Hospital
Russian Federation, MoscowReferences
- Авдеев С.Н., Дехнич А.В., Зайцев А.А., и др. Внебольничная пневмония: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2022;32(3):295-355 [Avdeev SN, Dekhnich AV, Zaytsev AA, et al. Federal guidelines on diagnosis and treatment of community-acquired pneumonia. Pulmonologiia. 2022;32(3):295-355 (in Russian)].
- Зайцев А.А. Эпидемиология заболеваний органов дыхания у военнослужащих и направления по совершенствованию пульмонологической помощи. Военно-медицинский журнал. 2018;339(11):4-9 [Zaitsev AA. Epidemiology of respiratory diseases among servicemen and directions of improvingpulmonological care. Voenno-meditsinskii zhurnal. 2018;339(11):4-9 (in Russian)].
- Зайцев А.А., Макаревич А.М., Паценко М.Б., Серговенцев А.А. Ошибки ведения больных с внебольничной пневмонией. Военно-медицинский журнал. 2022;343(12):24-37 [Zaitsev AA, Makarevich AM, Patsenko MB, Sergoventsev AA. Mistakes in the management of patients with community – acquired pneumonia. Voenno-meditsinskii zhurnal. 2022;343(12):24-37 (in Russian)].
- Смоленов И.В., Алексеева Я.Г., Смирнов Н.А. Роль неантибактериальных лекарственных средств в лечении пневмонии. Клиническая микробиология, антимикробная химиотерапия. 2002;3:233-8 [Smolenov IV, Alekseeva YaG, Smirnov NA. The role of non-antimicrobial drugs in the treatment of pneumonia. Klinicheskaia mikrobiologiia, antimikrobnaia khimioterapiia. 2002;3:233-8 (in Russian)].
- Белевский А.С. Современные возможности адъювантной терапии внебольничной пневмонии. Фарматека. 2013;6(259):49-52 [Belevskii AS. Sovremennye vozmozhnosti ad"iuvantnoi terapii vnebol'nichnoi pnevmonii. Farmateka. 2013;6(259):49-52 (in Russian)].
- Крюков Е.В., Зайцев А.А., Чернецов В.А., и др. Современные возможности и ограничения адъювантной терапии внебольничной пневмонии. Медицинский вестник МВД. 2017;1(86):32-5 [Kriukov EV, Zaytsev AA, Chernetsov VA, et al. Sovremennyie vozmozhnosti i ogranicheniia ad"iuvantnoi terapii vnebol'nichnoi pnevmonii. Meditsinskii vestnik MVD. 2017;1(86):32-5 (in Russian)].
- Зайцев А.А., Оковитый С.В., Крюков Е.В. Кашель. Практическое пособие для врачей. М., 2015 [Zaytsev AA, Okovityy SV, Kriukov EV. Kashel'. Prakticheskoie posobiie dlia vrachei. Moscow, 2015 (in Russian)].
- Авдеев С.Н., Батын С.З., Мержоева З.М., и др. Высокие дозы N-ацетилцистеина при остром респираторном дистресс-синдроме. Вестник анестезиологии и реаниматологии. 2010;5:3-11 [Avdeiev SN, Batyn SZ, Merzhoieva ZM, et al. Vysokiie dozy N-atsetiltsisteina pri ostrom respiratornom distress-sindrome. Vestnik anesteziologii i reanimatologii. 2010;5:3-11 (in Russian)].
- Lai K, Ng W, Osburga Chan P, et al. High-dose N-acetylcysteine therapy for novel H1N1 influenza pneumonia. Ann Intern Med. 2010;152(10):687-8.
- Ismail H. Bronchipret in cases of acute bronchitis. Schw Zschr Ganzheits Medizin. 2003:171-5.
- Kardos P, Berck H, Fuchs KH, et al. Leitlinie der Deutschen Gesellschaft fur Pneumologie und Beatmungsmedizin zur Diagnostik und Therapie von erwachsenen Patienten mit akutem und chronischem. Pneumologie. 2019;73:143-80.
- Kemmerich B. Evaluation of efficacy and toler-ability of a fixed combination of dry extracts of thyme herb and primrose root in adults suffering from acute bronchitis with productive cough. A prospective, double-blind, placebo-controlled multicentre clinical trial. Arzneimittelforschung. 2007;57(9):607-15.
- Kemmerich B, Eberhardt R, Stammer H. Efficacy and tolerability of a fluid extract combination of thyme herb and ivy leaves and matched placebo in adults suffering from acute bronchitis with productive cough. A prospective, double-blind, placebo-controlled clinical trial. Arzneimittelforschung. 2006;56(9):652-60.
- Семаш Н.А., Тюрин И.Е., Белевский А.С., Вязьменова Н.И. Высокие дозы N-ацетилцистеина при внебольничной пневмонии. Лечебное дело. 2012;2:81-6 [Semash NA, Tiurin IE, Belevskii AS, Viaz'menova NI. Vysokie dozy N-atsetiltsisteina pri vnebol'nichnoi pnevmonii. Lechebnoe delo. 2012;2:81-6 (in Russian)].
- Авдеев С.Н., Карчевская Н.А., Баймаканова Г.Е., и др. Годичное наблюдение за больными, перенесшими острое повреждение легких/острый респираторный дистресс-синдром, вызванный вирусом гриппа А/H1N1. Пульмонология. 2011;4:58-66 [Avdeev SN, Karchevskaia NA, Baimakanova GE, Cherniak AV. A one-year follow-up study of patients survived after ALI/ARDS caused by influenza A/H1N1. Pulmonologiia. 2011;4:58-66 (in Russian)].
